Vincristina Sulfate

Orer(France), Eli Lilly(United States of America)

Vincristine sulfate is an anticarcinogenic drug that is used to treat various types of tumors. It belongs to the pharmacological group of alkaloids and other cytostatic drugs of plant origin.

The drug is manufactured by several companies in different countries around the world, including Belgium, Australia, France and the United States of America. Vincristine is the international name of the drug, but it is also known by various synonyms such as Vero-Vincristine, Vincristine-LENS, Vincristine-Richter, Vincristine-Teva, Oncocristine, Cytocristine and Cytomide.

Dosage forms include lyophilized powder for the preparation of injection solution 1 mg, solution for injection 1 mg/ml, solution for injection 1 mg, solution for injection 2 mg and powder for injection solution 1 mg/ml. The active substance is Vincristine.

The drug is used to treat various types of tumors, such as acute lymphoblastic leukemia, lymphogranulomatosis, non-Hodgkin lymphomas, rhabdomyosarcoma, bone and soft tissue sarcomas, Ewing sarcoma, neuroblastoma, Wilms tumor, breast cancer, epithelioma, small cell lung cancer, idiopathic thrombocytopenic purpura, solid tumors in adults as a component of chemotherapy.

However, the drug also has contraindications. It should not be used for hypersensitivity, bone marrow hypoplasia, diseases of the nervous system, pregnancy and breastfeeding.

The drug may cause side effects such as abdominal pain, nausea, paralytic ileus, neuropathy, loss of some types of sensitivity and tendon reflexes, severe paresthesia, jaw pain, ataxia, decreased muscle strength, cranial nerve damage, alopecia, moderate leukopenia, thrombocytopenia, impaired ADH secretion, polyuria, dysuria, fever.

The drug may also interact with other drugs, reducing the effect of anti-gout drugs, increasing some of the unpleasant side effects caused by other drugs, such as neurotoxicity and myelosuppression. Therefore, it is necessary to carefully study all possible interactions with other drugs that the patient may be taking before starting treatment with Vincristine.

In general, treatment with Vincristine should only be carried out under the supervision of a qualified physician and only after a thorough review of the patient's medical history and health status.